AbbVie vs Johnson & Johnson

AbbVie (ABBV), health care, and Johnson & Johnson (JNJ), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Johnson & Johnson is worth $675.5B on the stock market and AbbVie $518.6B: Johnson & Johnson is valued at 30% more. AbbVie trades at 50.5 times earnings and Johnson & Johnson at 42.6. Over the past year AbbVie's share price has moved +25.9% and Johnson & Johnson's +41.3%.

Key facts

AbbVie market value
$518.6B
Johnson & Johnson market value
$675.5B
AbbVie P/E
50.5
Johnson & Johnson P/E
42.6
AbbVie revenue
$61.2BFY to 2025-12-31
Johnson & Johnson revenue
$94.2BFY to 2025-12-28
Superinvestors holding both
10

Market values as of .

AbbVie vs Johnson & Johnson: every measure side by side
Measure AbbVie Johnson & Johnson
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-28
Size
Market cap$518.6Blower$675.5Bhigher
Revenue$61.2Blower$94.2Bhigher
Earnings$4.2Blower$26.8Bhigher
Employees57,000lower138,200higher
Total assets$134Blower$199.2Bhigher
Valuation
P/E50.5higher42.6lower
P/S8.5higher7.2lower
P/B—8.3
Dividend yield2.35%higher1.87%lower
Profitability
Operating margin24.6%—
Balance sheet
Net assets-$3.3Blower$81.5Bhigher
Total liabilities$137.2Bhigher$117.7Blower
Total debt$67.5Bhigher$47.9Blower
Cash on hand$5.2Blower$19.7Bhigher
Price change
Today-0.39%higher-0.68%lower
1 year+25.9%lower+41.3%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Johnson & Johnson). Who owns ABBV · Who owns JNJ

Further comparisons

Learn

Questions and answers

Which is bigger, AbbVie or Johnson & Johnson?

By market value, Johnson & Johnson is the larger: $675.5B against $518.6B for AbbVie. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $61.2B for AbbVie.

Which has the higher P/E ratio?

AbbVie: 50.5, against 42.6 for Johnson & Johnson. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

AbbVie: 2.35%, against 1.87% for Johnson & Johnson. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

AbbVie: $67.5B, against $47.9B for Johnson & Johnson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AbbVie and Johnson & Johnson?

In their latest 13F filings, Fred DiSanto, Ken Fisher, Ken Griffin, Cliff Asness, Mairs & Power team, Jensen team, Murray Stahl, Thomas Russo, Howard Gleicher and Rajiv Jain hold both.

Cite this page

Funkfolio, “AbbVie vs Johnson & Johnson”, data as of 17 November 2026. https://funkfolio.com/compare/abbv-vs-jnj

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.